Drug Trial Radar · NCT07112222
A Study of LM-350 in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Aug 28, 2025
Primary completion
Jun 30, 2028
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- LaNova Medicines LimitedIndustry
- Sponsor type
- Industry
- First posted
- Aug 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
For Phase I Dose Escalation Stage, to assess the safety and tolerability of LM-350 in patients with advanced solid tumors,determine the maximum tolerated dose (MTD) or optimal biological dose (OBD), and explore the relationship between the biomarkers and the anti-tumor activity of LM-350. For Phase II Dose Expansion Stage, to assess the preliminary anti-tumor activity of LM-350 in patients with advanced solid tumors.
Conditions
- Malignant Tumors
Interventions
LM-350 for injectionDrug
Q3W,Intravenous Drip
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limitingtoxicity (DLT)Time frame: 78 weeks
- Incidence of Treatment-Emergent Adverse Events (AEs)Time frame: 78 weeks
- Incidence of serious adverse events (SAEs)Time frame: 78 weeks
- Temperature (Celsius)Time frame: 78 weeks
- Pulse in BPM(Beat per Minute)Time frame: 78 weeks
- Blood Pressure in mmHgTime frame: 78 weeks
- Weight in KgTime frame: 78 weeks
- Height in centimeterTime frame: 78 weeks
- Blood Routine examination -> Complete Blood CountTime frame: 78 weeks
- Urine Routine examination ->UrinalysisTime frame: 78 weeks
- Blood Biochemistry test -> Electrolytes and Metabolic ParametersTime frame: 78 weeks
- Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalizedTime frame: 78 weeks
- Pregnancy testTime frame: 78 weeks
- Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentageTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in HRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in RRTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QRSTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTTime frame: 78 weeks
- 12-lead electrocardiogram (ECG) in QTcFTime frame: 78 weeks
- ECOG(Eastern Cooperative Oncology Group) scoreTime frame: 78 weeks
- Objective Response Rate (ORR)Time frame: 130 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Cancer Care Wollongong Pty Limited
Wollongong, New South Wales, Australia · Recruiting
Cancer Research SA
Adelaide, South Australia, Australia · Recruiting
Peninsula and South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia · Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.